GlassScriptPhysician profile
John R Feeney
NPI 1528049475
$1,881.63
in general payments reported to CMS, 2019-2025
33 companies · $701 in 2025
The $701 reported for 2025 was more than what 79% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $98.21 · 2023: $68.89 · 2024: $544 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $284.94 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $185.58 | 2019-2024 | |
| Glaxosmithkline, LLC. | $174.22 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Amgen INC. | $134.15 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $117.76 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $107.21 | 2024-2025 | Belbuca |
| Merck Sharp & Dohme LLC | $84.01 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Exact Sciences Corporation | $82.69 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $77.43 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Hologic Sales and Service, LLC | $76.27 | 2020-2025 | Aptima |
| Verity Pharmaceuticals INC. | $48.86 | 2025 | Tlando |
| Mannkind Corporation | $39.24 | 2019 | |
| Phathom Pharmaceuticals, INC. | $33.05 | 2024 | Voquezna |
| Boston Scientific Corporation | $32.63 | 2025 | Wavewriter Alpha Prime 16 |
| Astellas Pharma US INC | $31.96 | 2024 | Veozah |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $31.49 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.51 | 2019-2020 | |
| Medtronic, INC. | $29.65 | 2024 | Linq II |
| Aimmune Therapeutics, INC. | $25.81 | 2025 | Zenpep |
| Edwards Lifesciences Corporation | $24.37 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Allergan, INC. | $22.80 | 2020 | |
| Antares Pharma, INC. | $22.04 | 2019 | |
| Optinose US, INC. | $21.88 | 2025 | |
| Avanir Pharmaceuticals, INC. | $21.53 | 2019 | |
| Medtronic Vascular, INC. | $20.67 | 2019 | |
| Tolmar, INC. | $20.17 | 2025 | Jatenzo |
| Phadia US INC. | $16.93 | 2024 | Immunocap |
| Sumitomo Pharma America, INC. | $15.31 | 2025 | Gemtesa |
| Sanofi Pasteur INC. | $15.20 | 2019 | |
| Genentech USA, INC. | $14.73 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.43 | 2019 | |
| Novo Nordisk INC | $12.18 | 2020 | |
| Amarin Pharma, INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Feeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.